Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
9 Results for "
hemorrhagic lesion
" in MedChemExpress (MCE) Product Catalog:
Products (9)
9 Results for "hemorrhagic lesion" in MCE Product Catalog:
1
1 Cited Publications
Cat. No.: HY-P1108
CAS No.: 681260-70-8
Target:
Research Areas:
Cat. No.: HY-162596
CAS No.: 1973494-16-4
Synonyms: BA-1049 free base
Target:
Research Areas:
NRL-1049 (BA-1049 (free base)) is an orally available and selective ROCK2 inhibitor with IC50 values of 0.59 µM for ROCK2 and 26 µM for ROCK1, respectively. NRL-1049 modulates ROCK signaling, preserves blood-brain barrier integrity, reduces edema, seizures and hemorrhage, and alleviates cerebral cavernous malformation lesion burden. NRL-1049 can be used for the study of acute brain injury, ischemic stroke, and cerebral cavernous malformations .
Cat. No.: HY-N6726
CAS No.: 1422359-85-0
Target:
Cat. No.: HY-N6726S
CAS No.: 2819816-90-3
Cat. No.: HY-120381
CAS No.: 139067-52-0
Synonyms: CAM 1189
Target:
Research Areas:
PD 136450 (CAM 1189) is an antagonist for cholecystokinin 2 (CCK2). PD 136450 exhibits anti-secretory, anxiolytic and anti-ulcer activities, inhibits gastric acid secretion (IC50=1 mg/kg), and ameliorates the haemorrhagic lesions (IC50=4.7 mg/kg) in rats .
Cat. No.: HY-167824
CAS No.: 298198-52-4
Target:
Research Areas:
SSR180711 is a potent and subtype-selective α7 agonist with activity in Alzheimer's disease and schizophrenia research. SSR180711 can be used to study subtypes of intracerebral hemorrhage associated with cerebral small vessel disease. SSR180711 shows potential in electrophysiological and behavioral studies to evaluate its effects on cognitive function. SSR180711 also has potential for studying cerebrovascular lesions and their effects .
Cat. No.: HY-N6726R
CAS No.: 1422359-85-0
Category:
Cat. No.: HY-N6726S1
CAS No.: 1217494-88-6
Cat. No.: HY-162596A
CAS No.: 863638-93-1
Synonyms: (Rac)-BA-1049
Target:
Research Areas:
(Rac)-NRL-1049 is the racemic mixture of NRL-1049 (BA-1049 (free base)) (HY-162596). NRL-1049 is an orally available and selective ROCK2 inhibitor with IC50 values of 0.59 µM for ROCK2 and 26 µM for ROCK1, respectively. NRL-1049 modulates ROCK signaling, preserves blood-brain barrier integrity, reduces edema, seizures and hemorrhage, and alleviates cerebral cavernous malformation lesion burden. NRL-1049 can be used for the study of acute brain injury, ischemic stroke, and cerebral cavernous malformations .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
